Document is current
Any future updates will be listed below
-
Authors
Ternant, David https://orcid.org/0000-0003-4020-4545
Le Tilly, Olivier
Cartron, Guillaume
Desvignes, Céline
Bensalem, Amina
Mulleman, Denis
Bejan-Angoulvant, Theodora
Gouilleux-Gruart, Valérie
Paintaud, Gilles
-
Funding
Funding for this research was provided by:
CHRU de Tours
- License Information
-
More Information
Article History
Accepted: 6 July 2025
First Online: 14 August 2025
Declarations
:
: This study used rituximab pharmacokinetic data belonging to the Lymphoma Study Association (LYSA, France), the French Innovative Leukemia Organization (FILO, France), the Mayo Clinic (Rochester, MN, USA), and Tours University Hospital (Tours, France). The study in patients with DLBCL or follicular lymphoma was funded by GELA and GOELAMS groups and F. Hoffman-La Roche Ltd (Basel, Switzerland). The study in patients with CLL was funded by the FILO Group and Roche SAS (Neuilly, France). Measurements of rituximab serum concentrations in patients with CLL, DLBCL, follicular lymphoma (FL), or RA were carried out via the CePiBAc platform. CePiBAc was co-financed by the EU. Europe is committed to the region Centre with the European Regional Development Fund. CePiBAc was partly supported by the French Higher Education and Research ministry under the program ‘Investissements d’avenir’ grant agreement: LabEx MAbImprove ANR-10-LABX-53-01.
: Theodora Bejan-Angoulvant has no conflicts of interest to declare. She can be added to the lists of authors with no conflict of interest, for instance 'Céline Desvignes, Theodora Bejan-Angoulvant and Valérie Gouilleux-Gruart have no conflicts of interest to declare
: All studies were approved by the local ethics committee, and all patients provided written informed consent. Samples from the registered single-center cohort (University Hospital of Tours, France) with RA were primarily used for therapeutic drug monitoring routine, are part of a declared biological collection (N◦DC2016–2739), and conformed with the National Data Information and Freedom Commission. All data sets were anonymized before data analysis.
: Patients provided written informed consent, which included consent to participate.
: Patients provided written informed consent, which included consent for publication.
: Data and material and code are available upon request to the corresponding author.
: Code is available upon request to the corresponding author.
: Céline Desvignes contributed to materials, participated in data management and reviewed the manuscript. Theodora Bejan-Angoulvant analyzed the data, interpreted the results and reviewed the manuscript.
